Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy
Nutritional metal ions play critical roles in many important immune processes. Hence, the
effective modulation of metal ions may open up new forms of immunotherapy, termed as …
effective modulation of metal ions may open up new forms of immunotherapy, termed as …
Combination strategies to maximize the benefits of cancer immunotherapy
S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu… - Journal of hematology & …, 2021 - Springer
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin… - Nature medicine, 2022 - nature.com
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
Epigenetic regulation of T cell exhaustion
Chronic antigen stimulation during viral infections and cancer can lead to T cell exhaustion,
which is characterized by reduced effector function and proliferation, and the expression of …
which is characterized by reduced effector function and proliferation, and the expression of …
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …